Scrip regularly reviews technology transfer activity across the biopharmaceutical sector. Recent editions of Tech Transfer Roundup focused on oncology and COVID-19 deals. This reviews the rest of the deals from the same time period.
Neuromuscular and pulmonary disease-focused Santhera Pharmaceuticals said on 28 February that it will license to SEAL Therapeutics AG,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?